Lancet oncol: Efficacy and safety of Pym monoantigen treatment of non-small cell lung cancer with untreated brain metastasis

Goldberg et alconducted phase 2 trials of pembrolizumab (Pym monoantigen) in patients with non-small cell lung cancer (NSCLC) or melanoma with untreated brain metastasis to determine the activity of PD-1 blockinst in the central nervous system (CNS)Interim results have been published before, and this article now reports on the latest analysis of the entire NSCLC queuethis trial is an open Phase 2 trial that recruited at least one phase 5-20mm brain metastatic type of NSCLC patient over the age of 18 with a 5-20mm brain metastatic tumor, and asked subjects to progress, no neurological symptoms or corticosteroid needs after radiotherapy, and an ECOG performance score of 0-1The patient received Pym mono-resistance of 10mg/kg week (static drops)All patients were divided into two queues, with a queue of 1:PD-L1 expression of 1% and a queue of 2:PD-L1 expression of 1%The main node is the proportion of patients who receive brain metastasis (partial or complete remission)from March 31, 2014 to May 21, 2018, a total of 42 patients were includedMedian follow-up 8.3 monthsEleven patients in cohort 1 received brain metastasisNo patients in queue 2 were relievedTreatment-related level 3-4 adverse reactions were pneumonia (2 cases) and physical symptoms, colitis, adrenal insufficiency, high blood sugar, hypokalemia (1 case each)There were 6 cases (14%) of treatment-related severe adverse reactions: pneumonia (2 cases), acute kidney injury (1 case), colitis (1 case), hypokalemia (1 case) and renal insufficiency (1 case)No treatment-related deathsPymmono-resistant non-small cell lung cancer patients with untreated brain metastasis of PD-L1 expression of 1% had therapeutic activity and better safetyIt deserves further study